Pfizer Inc. (NYSE: PFE) is buying InnoPharama in a deal valued at up to $360 million.

InnoPharma is a pharmaceutical company that owns 10 generic products that are approved by the U.S. Food and Drug Administration. The company's product pipeline includes 19 more products that have been filed with the FDA and more than 30 injectable and ophthalmic drugs in development.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.